A detailed history of Parallel Advisors, LLC transactions in Vaxart, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 3,000 shares of VXRT stock, worth $2,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,000
Previous 3,000 -0.0%
Holding current value
$2,040
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$0.56 - $1.41 $464 - $1,170
-830 Reduced 21.67%
3,000 $3,000
Q2 2023

May 20, 2024

SELL
$0.6 - $1.41 $57 - $135
-96 Reduced 2.45%
3,830 $2,000
Q2 2023

Aug 04, 2023

SELL
$0.6 - $1.41 $57 - $135
-96 Reduced 2.45%
3,830 $2,000
Q1 2023

May 20, 2024

BUY
$0.71 - $1.25 $657 - $1,157
926 Added 30.87%
3,926 $2,000
Q4 2022

Feb 03, 2023

BUY
$0.75 - $2.24 $18 - $56
25 Added 0.64%
3,926 $3,000
Q2 2022

Aug 01, 2022

BUY
$2.7 - $5.28 $8,100 - $15,840
3,000 Added 332.96%
3,901 $14,000
Q1 2022

Apr 28, 2022

SELL
$4.29 - $6.64 $2,428 - $3,758
-566 Reduced 38.58%
901 $4,000
Q4 2021

Jan 20, 2022

SELL
$5.77 - $7.96 $1,177 - $1,623
-204 Reduced 12.21%
1,467 $9,000
Q1 2021

Apr 23, 2021

BUY
$5.64 - $23.33 $1,923 - $7,955
341 Added 25.64%
1,671 $10,000
Q4 2020

Feb 02, 2021

BUY
$3.5 - $7.98 $1,225 - $2,793
350 Added 35.71%
1,330 $8,000
Q3 2020

Oct 27, 2020

BUY
$4.78 - $16.97 $1,238 - $4,395
259 Added 35.92%
980 $7,000
Q2 2020

Jul 16, 2020

SELL
$1.68 - $8.85 $2,822 - $14,868
-1,680 Reduced 69.97%
721 $6,000
Q1 2020

Apr 27, 2020

SELL
$0.34 - $2.87 $2,720 - $22,960
-8,000 Reduced 76.92%
2,401 $4,000
Q4 2019

Jan 30, 2020

BUY
$0.28 - $0.39 $980 - $1,365
3,500 Added 50.72%
10,401 $4,000
Q3 2019

Nov 01, 2019

BUY
$0.3 - $0.75 $2,070 - $5,175
6,901 New
6,901 $2,000

Others Institutions Holding VXRT

About Vaxart, Inc.


  • Ticker VXRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,506,000
  • Market Cap $86M
  • Description
  • Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...
More about VXRT
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.